Lupin Limited has announced a significant board appointment, naming Mr. Anand Kripalu as Additional Director (Non-Executive, Independent) effective February 01, 2026. The pharmaceutical company's Board of Directors unanimously approved this strategic appointment during their meeting held on January 06, 2026.

Board Appointment Details

The appointment was made based on the recommendation of the Nomination and Remuneration Committee. Key details of Mr. Kripalu's appointment are outlined below:

Professional Background and Expertise

Mr. Anand Kripalu brings over three decades of extensive industry experience in the fast-moving consumer goods sector. His distinguished career spans multiple leadership roles across prominent organizations:

• Current Role: Executive Director of EPL Limited (previously Managing Director and Global CEO until December 31, 2025)
• Previous Leadership Positions: MD & CEO of Diageo India, President of India and South-East Asia at Mondelez International (Cadbury)
• Early Career: More than 20 years at Unilever in various general management, sales and marketing roles

Educational Qualifications and Recognition

Mr. Kripalu's academic credentials include:

• MBA from IIM, Calcutta
• B. Tech (Electronics) from IIT Madras
• Advanced Management Program from Wharton Business School
• Distinguished Alumnus Award recipient from both IIM and IIT

Current Directorships and Awards

Beyond his executive roles, Mr. Kripalu serves as Independent Director at Swiggy Limited and United Breweries Limited, and was previously a director at Marico Limited. His industry contributions have been recognized with the "Lifetime Achievement Award" at the 8th edition of the Indian Marketing Awards by exchange4media.

Regulatory Compliance

Lupin Limited confirmed that based on available information, Mr. Anand Kripalu is not debarred from holding the office of Director by virtue of any order passed by SEBI or any other authority. The company also disclosed that Mr. Kripalu is not related to any of the Directors, Key Managerial Personnel, or Promoters of the Company.

Meeting Details

The Board meeting that approved this appointment commenced at 07:00 p.m. (IST) and concluded at 08:50 p.m. (IST) on January 06, 2026. The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Lupin Ltd. has secured exclusive rights to commercialize and distribute Bofanglutide, a fortnightly injectable GLP-1 drug for diabetes and obesity management, in India through a strategic licensing agreement with China-based Gan & Lee Pharmaceuticals. The partnership positions the pharmaceutical company to expand its presence in the diabetes and obesity management segments with an innovative drug offering.

Strategic Partnership Details

The exclusive licensing, supply and distribution agreement grants Lupin comprehensive rights for the Indian market. The collaboration focuses on Bofanglutide, a fortnightly injectable GLP-1 drug that represents a significant advancement in diabetes and obesity treatment protocols.

Drug Characteristics and Competitive Advantages

Bofanglutide is positioned as potentially first-in-class globally, with clinical data demonstrating weight loss efficacy comparable to or better than existing GLP-1 therapies. The drug's primary differentiator lies in its dosing frequency, requiring administration only once every two weeks compared to the weekly injections required for current GLP-1 treatments.

The reduced dosing frequency addresses a significant patient compliance challenge in diabetes and obesity management. This convenience factor could enhance treatment adherence and improve patient outcomes in the Indian market.

Portfolio Impact and Market Position

This agreement strategically strengthens Lupin's diabetes treatment drug portfolio while simultaneously accelerating its entry into the obesity treatment segment. The partnership aligns with the growing demand for innovative diabetes management solutions and the emerging focus on obesity as a critical health concern.

The exclusive rights for India provide Lupin with a competitive advantage in a large and growing market for diabetes and obesity treatments.

Analyst Coverage and Stock Performance

Lupin maintains strong analyst coverage with 40 analysts tracking the stock. The analyst sentiment reflects cautious optimism about the company's prospects.

The stock closed the previous session at ₹2,082.00 per share, declining 1.40% during the trading session. Year-to-date performance shows the stock has declined 11.90%, reflecting broader market challenges and sector-specific factors affecting pharmaceutical companies.